Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice
Abstract Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway, which is critical in regulating the gliogen...
Guardado en:
Autores principales: | Han-Chung Lee, Hamizun Hamzah, Melody Pui-Yee Leong, Hadri Md Yusof, Omar Habib, Shahidee Zainal Abidin, Eryse Amira Seth, Siong-Meng Lim, Sharmili Vidyadaran, Mohamad Aris Mohd Moklas, Maizaton Atmadini Abdullah, Norshariza Nordin, Zurina Hassan, Pike-See Cheah, King-Hwa Ling |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b2cbcfa33d8b42fb93d9fbc95b27e345 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Ruxolitinib as an emerging treatment in myelofibrosis
por: Emanuel RM, et al.
Publicado: (2013) -
Ruxolitinib: a targeted treatment option for patients with polycythemia vera
por: Vaddi K, et al.
Publicado: (2016) -
Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma.
por: Fani Karagianni, et al.
Publicado: (2021) -
Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
por: Jack W Singer, et al.
Publicado: (2019) -
Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients
por: Wei C, et al.
Publicado: (2021)